Cheniere Energy, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Cheniere Energy, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.98B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $15.70B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $20.39B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $33.43B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $15.86B | Feb 22, 2024 |
| FY2020 | Dec 31, 2020 | $2.79B | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | $1.46B | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | $2.40B | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | $2.71B | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | $3.01B | Feb 24, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.46B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $15.41B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $19.78B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $33.31B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $17.53B | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $9.29B | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $9.16B | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $7.90B | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $5.65B | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $1.28B | Feb 26, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $267.21M | Feb 21, 2014 |
| FY2012 | Dec 31, 2012 | $266.22M | Feb 22, 2013 |
| FY2011 | Dec 31, 2011 | $290.44M | Mar 22, 2012 |
| FY2011 | Dec 31, 2010 | $291.51M | Mar 22, 2012 |
| FY2011 | Dec 31, 2009 | $181.13M | Mar 22, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.33B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $3.25B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $9.88B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $1.43B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | ($2.34B) | Feb 22, 2024 |
| FY2020 | Dec 31, 2020 | ($194.00M) | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | ($463.00M) | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | $197.00M | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | $375.00M | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | $939.00M | Feb 24, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.11B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $6.13B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $15.49B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $4.56B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | ($701.00M) | Feb 22, 2024 |
| FY2020 | Dec 31, 2020 | $276.00M | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | $72.00M | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | $937.00M | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | $1.35B | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | $1.02B | Feb 24, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $16.00M | Feb 23, 2023 |
| FY2022 | Dec 31, 2021 | $7.00M | Feb 23, 2023 |
| FY2022 | Dec 31, 2020 | $6.00M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $9.00M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $7.00M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $10.00M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $7.00M | Feb 26, 2019 |
| FY2017 | Dec 31, 2015 | $42.00M | Feb 21, 2018 |
| FY2016 | Dec 31, 2014 | $54.38M | Feb 24, 2017 |
| FY2015 | Dec 31, 2013 | $60.93M | Feb 19, 2016 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $383.00M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $441.00M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $474.00M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $416.00M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $325.00M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $302.00M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $310.00M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $289.00M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $256.00M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $260.00M | Feb 26, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.54B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $5.39B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $8.42B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $10.52B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $2.47B | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $1.27B | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $1.83B | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $1.99B | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $1.23B | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | ($404.00M) | Feb 26, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.08B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $2.24B | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $2.12B | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $1.83B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $966.00M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $1.84B | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $3.06B | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $3.64B | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $3.36B | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $4.36B | Feb 26, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $47.88B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $43.86B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $43.08B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $41.27B | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $39.26B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $35.70B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $35.49B | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $31.99B | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $27.91B | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $23.70B | Feb 21, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $34.80B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $33.80B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $34.06B | Feb 20, 2025 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.92B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $5.70B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $5.06B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | ($2.97B) | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | ($2.57B) | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | ($191.00M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($14.00M) | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | ($526.00M) | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | ($1.76B) | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | ($1.40B) | Feb 21, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $77.00M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $77.00M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $77.00M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $77.00M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $77.00M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $77.00M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $77.00M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $77.00M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $77.00M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $77.00M | Feb 21, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.24B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $7.38B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $4.55B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | ($4.94B) | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | ($6.02B) | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | ($3.59B) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($3.51B) | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | ($4.16B) | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | ($4.63B) | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | ($4.23B) | Feb 21, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.10B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $2.64B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $4.07B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $1.35B | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $1.40B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $1.63B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $2.47B | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $981.00M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $722.00M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $876.00M | Feb 21, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.51B | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $22.55B | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $23.40B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $24.06B | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $29.45B | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $30.47B | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $30.77B | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $28.18B | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $25.34B | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $21.69B | Feb 21, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 24 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 14 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 40 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 5 | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | (9) | Feb 22, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | (1) | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | 1 | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | 3 | Feb 24, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 24 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 14 | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | 40 | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | 5 | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | (9) | Feb 22, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Sep 30, 2020 | (1) | Feb 24, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 24, 2021 |
| FY2020 | Mar 31, 2020 | 1 | Feb 24, 2021 |
| FY2020 | Dec 31, 2019 | 3 | Feb 24, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | 253.60M | Feb 24, 2022 |
| FY2021 | Dec 31, 2020 | 252.30M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | 253.60M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | 257.00M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | 237.60M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | 238.00M | Feb 21, 2018 |
| FY2016 | Dec 31, 2015 | 235.64M | Feb 24, 2017 |
| FY2015 | Dec 31, 2014 | 236.75M | Feb 19, 2016 |
| FY2014 | Dec 31, 2013 | 238.09M | Feb 20, 2015 |
| FY2012 | Dec 31, 2012 | 223.40M | Feb 22, 2013 |